Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mezigdomide · BMS-986348, CC-92480

Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN) · developed by BRISTOL MYERS SQUIBB

Phase 3 Most advanced trial

BMY Developer

1 Registered trials

What is Mezigdomide?

Mezigdomide is a cereblon (CRBN) modulator that binds to CRBN and enhances the ubiquitin E3 ligase activity of the CRL4-CRBN complex, targeting substrate proteins for proteasomal degradation. This induces T-cell activation and downregulates proteins involved in cancer cell proliferation. It is studied in relapsed or refractory multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BMS-986348, CC-92480
Drug type: Small molecule (Molecular glue degrader)
Targets: cereblon (CRBN)
Mechanism: Degrader of cereblon (CRBN)
Pathways: proteasome-mediated degradation, T-cell activation
Therapy area: Oncology
Developer: BRISTOL MYERS SQUIBB (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: LA88IH4O02

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05552976	Phase 3	Relapsed or Refractory Multiple Myeloma	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed or Refractory Multiple Myeloma

Other drugs acting on CRBN

Cemsidomide Phase 2

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Mezigdomide

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z